The short answer
CBD may add to metaxalone-related drowsiness or impairment, depending on the preparation and dose. Exact-pair risk is not quantified, and evidence from one cannabinoid product cannot be applied to all hemp or cannabis products.
What this answer covers
Cannabidiol products; prescription purified oral CBD, retail oils, THC-containing mixtures and topical products are not equivalent.
- Supplement or preparation
- Cannabidiol
- Medication ingredient
- metaxalone
Both exposures can affect alertness
Metaxalone can cause CNS depression. Prescription cannabidiol labeling also describes sedation and warns about other CNS depressants. The prescription CBD doses and patient population do not define the risk of every retail product.
A controlled cannabis study shows why composition matters
An oral THC-plus-high-dose-CBD condition caused more impairment than the same THC dose alone. The study had no CBD-only arm and included other probe medicines, so it cannot measure this metaxalone combination.
Keep product and formulation distinctions
Hemp food, a topical product and an oral or inhaled intoxicating preparation are different exposures. Metaxalone 640 mg and 800 mg products also have distinct instructions and should not be substituted milligram-for-milligram.
Review co-use before driving or changing doses
Show the prescriber the exact cannabinoid product and avoid driving while impaired. No safe combined dose or protective short gap is established. Marked confusion, breathing difficulty or inability to wake needs urgent help.
Evidence and practical considerations
Side effects & toxicity
Conditional additive CNS-effect concern from metaxalone and cannabinoid evidence, with route/composition limits; no exact-pair rate, retail-dose equivalence or universal cannabis effect.
- Exact scope
- Cannabidiol products; prescription purified oral CBD, retail oils, THC-containing mixtures and topical products are not equivalent. with Metaxalone59078 IN; oral640mg/800mg formulation boundaries and non-opioid muscle-relaxant scope.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- No unmeasured pair incidence, blanket class transfer or arbitrary spacing interval.
Factors that may matter: Preparation; Dose; Other medicines; Organ function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed metaxalone
CNS depression and serotonin-syndrome precautions with serotonergic drugs; contraindicated with severe renal/hepatic impairment.
How this applies: Exact metaxalone RxCUI 59078 IN, with stated salt/formulation/route bridge.
640mg and 800 mg products are not mutually substitutable mg-for-mg; no supplement-specific incidence.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed metaxalone
Drowsiness/CNS-depressant and serotonin-syndrome warnings; food can affect exposure.
How this applies: Exact metaxalone RxCUI 59078 IN, with stated salt/formulation/route bridge.
Separate formulation instructions; not a pain opioid or evidence that every supplement is contraindicated.
Source 3: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed cannabidiol
Dose-related somnolence/sedation, influenced by co-medication; other CNS depressants may increase it.
How this applies: Cannabidiol-specific sedation evidence with prescription oral preparation and epilepsy-dose limits.
Not metaxalone combination data, low-dose retail CBD, topical hemp or proof of all-cannabis effects.
Source 4: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 18 healthy adults.
CBD-containing cannabis condition produced more sedation and impairment than THC alone; placebo-cocktail condition had no measured PD effects.
How this applies: No metaxalone, no CBD-only arm, high oral doses and probe-drug co-exposure; not every cannabis route or hemp product.
No metaxalone, no CBD-only arm, high oral doses and probe-drug co-exposure; not every cannabis route or hemp product.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact metaxalone article with formulation-specific evidence and uncertainty. | |
| Research summary published |
Article revision: 8b4e02217c24c4f1
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.